Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9652.
-
Palantir Stock Trends Higher Ahead of Earnings: What's Happening?Palantir Technologies shares are rising Monday as investors wait for its third-quarter earnings report, due after the market closes.
-
Solana Officially Scores 1,000 Days Without OutageSolana has officially reached 1,000 days without a network-wide outage, marking a major turnaround for a blockchain once notorious for frequent disruptions and highlighting significant improvements in network reliability.
-
BofA Revises CaixaBank Forecasts Following Q3 ResultsBank of America has updated its growth forecasts for CaixaBank following the release of the company's third-quarter 2026 financial results.
-
Framery Group Oyj Announces 2027 Financial Reporting CalendarFramery Group Oyj has released its scheduled dates for financial reporting and its Annual General Meeting for the 2027 calendar year.
-
Incap Corporation Reports Share Repurchase Activity for Week 44Incap Corporation announced its share repurchase activity for week 44 of 2026, conducted in accordance with European market regulations.
-
Framery Group Oyj Reports Q3 2026 Financial ResultsFramery Group Oyj announced its third-quarter 2026 financial results, reporting revenue of €53.4 million and an adjusted EBIT margin of 23.7%.
-
Finnair Selects SES for Multi-Orbit In-Flight Connectivity on New AircraftFinnair has entered into an agreement with SES to equip 18 of its Embraer E195-E2 aircraft with multi-orbit in-flight connectivity.
-
Enento Group Plc: Share Repurchase DisclosureEnento Group Plc reported its share repurchase activity for the week ending October 30, 2026.
-
Kamada to Announce Third Quarter 2026 Financial Results on November 9, 2026Kamada Ltd. has scheduled the release of its financial results for the third quarter and nine months ended September 30, 2026, for November 9, 2026.
-
Infineon Technologies AG Receives Goldman Sachs Voting Rights NotificationInfineon Technologies AG issued a regulatory announcement regarding a change in voting rights held by The Goldman Sachs Group, Inc.
-
Goldman Sachs Adjusts Generali Price TargetGoldman Sachs has lowered its price target for Assicurazioni Generali S.p.A. from 41.50 EUR to 41.30 EUR while maintaining a "Neutral" rating.
-
Safran Selected for Three French Nuclear Deterrence ProgramsSafran has been selected to provide its Hemispherical Resonating Gyroscope (HRG) technology for three French nuclear deterrence programs.
-
Glencore to adjust CEO compensation terms regarding potential takeoversGlencore is reportedly modifying CEO Gary Nagle's compensation package to protect his share awards in the event of a company takeover.
-
BrainsWay Announces Strategic Collaboration with Mindful Health SolutionsBrainsWay has entered into a strategic collaboration with Mindful Health Solutions to expand patient access to its Deep TMS and SWIFT treatment protocols.
-
Chloé Launches Festive 2026 Campaign Featuring Claudia SchifferRichemont's fashion house Chloé has unveiled its festive 2026 advertising campaign, starring supermodel Claudia Schiffer.
-
BASF SE Reports Share Buyback ProgressBASF SE announced the purchase of 355,128 shares between October 26 and October 30, 2026, as part of its ongoing share buyback program.
-
BNP Paribas Appointed for Share Repurchase ProgramBNP Paribas has been appointed to manage the on-market limb of a company's share repurchase program through January 2027.
-
Roche Receives FDA 510(k) Clearance for Cobas Eplex Respiratory Pathogen Panel 3Roche has obtained U.S. FDA 510(k) clearance for its new cobas eplex respiratory pathogen panel 3, a diagnostic tool designed to allow laboratories to customize respiratory testing.
-
Here's How Much $100 Invested In L3Harris Technologies 15 Years Ago Would Be Worth TodayL3Harris Technologies (NYSE:LHX) has outperformed the market over the past 15 years by 1.55% on an annualized basis producing an average annual return of 14.18%. Currently, L3Harris Technologies has a market
-
Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease ImmunotherapyInovio stock surges after FDA accelerated approval of Voceryq, an immunotherapy reducing surgeries for adults with recurrent respiratory papillomatosis.